Acumen Pharmaceuticals, Inc.
ABOSNASDAQHealthcare● Active
$2.17
+$0.02(+0.93%)
Market Cap$131444278
P/E Ratio—
52W High$3.6
52W Low$1.05
Acumen Pharmaceuticals, Inc. (ABOS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ABOS · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.01B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | ($0.01B) |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.10B | $0.09B | $0.04B | $0.03B | $0.01B |
| G&A Expenses | $0.02B | $0.02B | $0.02B | $0.01B | $0.01B |
| Total Operating Expenses | $0.12B | $0.11B | $0.06B | $0.05B | $0.01B |
| Operating Income | ($0.12B) | ($0.11B) | ($0.06B) | ($0.05B) | ($0.02B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.12B) | ($0.10B) | ($0.05B) | ($0.04B) | ($0.10B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.12B) | ($0.10B) | ($0.05B) | ($0.04B) | ($0.10B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.00 | $-1.71 | $-1.08 | $-1.06 | $-2.63 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.05B | 0.04B | 0.04B |
| EBITDA | ($0.12B) | ($0.10B) | ($0.05B) | ($0.04B) | ($0.02B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Acumen Pharmaceuticals, Inc. data
About Acumen Pharmaceuticals, Inc. (ABOS) Income Statement
Acumen Pharmaceuticals, Inc. (ABOS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ABOS reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.12B) — a net profit margin of —.
Frequently asked questions
ABOS · 4 questionsAcumen Pharmaceuticals, Inc. (ABOS) reported revenue of $0.00B for 2025, down —% year-over-year.
ABOS revenueABOS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09